Search results | Shionogi

Reports

Partnering Agreements for Shionogi

This report provides all the information you require to better understand Shionogi and its partnering interests and activities over the past seven years.

Insights

Shionogi

Shionogi is a top pharmaceutical company based in Osaka, Japan

Shionogi: Strategically positioned in the global market

Shionogi is a Japanese based large pharmaceutical company specialising in the manufacture and distribution of pharmaceuticals, diagnostic reagents and medical devices.

Shionogi: M&A activity 2005-2013

Shionogi has announced only 2 M&A deals since 2005, with the deals being the acquisition of C&O Pharmaceutical Technology and Sciele Pharma.

Shionogi: Partnering activity 2005-2013

Shionogi announced over 30 partnering / licensing deals since 2005, with almost consistent dealmaking deals in 2010. Analysis of the partnering deals shows a strong emphasis on partnerships in infectives, CNS and respiratory diseases.

Shionogi: Company Profile

Shionogi, a top pharmaceutical company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years

Mylan settles pharma partnering dispute with Shionogi over generic Orapred ODT

Mylan & Shionogi, two top pharma companies agreed to mutually settle the pharma partnering dispute over the patent litigation rights related to the generic drug  Prednisolone Sodium Phosphate Orally Disintegrating Tablets (ODT), 10 mg, 15 mg and 30 mg

Ranbaxy

Ranbaxy Laboratories is a top pharmaceutical company based in Haryana, India

Purdue Pharma: Perfectionists in pain and partnering

US based Purdue Pharma is a top 50 pharma company specialising in the research and development of prescription and OTC pain treatments.

Current Agreements Deal Analysis Update : December 2013

This month we provide you with an overview of life science deal making activity, covering partnering, M&A and financing in November 2013

Ranbaxy: Company Profile

Ranbaxy Laboratories, a top pharmaceutical company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years

Events

Sorry, your search returned no results.


Deals

Shionogi enters into a pharma licensing deal for hydrocodone opioid products

Egalet has entered into a definitive collaboration and pharma licensing deal with Shionogi for the development and potential commercialization of multiple oral abuse-deterrent hydrocodone opioid product candidates using Egalet’s proprietary technology.

Big pharma partneirng ties: Shionogi in a pact with GSK & Viiv Healthcare for dolutegravir

Shionogi, a top 50 big pharma company will take a 10 percent stake in Viiv Healthcare, a AIDS drug joint venture between GlaxoSmithKline and Pfizer in a pharma partnering pact,  in exchange for its rights to the drug Dolutegravir

Mylan settles pharma partnering dispute with Shionogi over generic Orapred ODT

Mylan & Shionogi, two top pharma companies agreed to mutually settle the pharma partnering dispute over the patent litigation rights related to the generic drug  Prednisolone Sodium Phosphate Orally Disintegrating Tablets (ODT), 10 mg, 15 mg and 30 mg

Mylan & Shionogi settle pharma licensing rights dispute for Orapred ODT

Mylan, a top 50 pharma company has entered into a pharma licensing settlement agreement with Shionogi, a  big pharma and CIMA Labs that will resolve patent litigation related to Prednisolone Sodium Phosphate Orally Disintegrating Tablets (ODT), 10 mg, 15 mg and 30 mg

Big pharma alliances for infectious diseases drug development

Five Japanese life sciences giants pharma alliances with the Bill and Melinda Gates Foundation and Japan’s government to develop new medicines, vaccines, and diagnostics for infectious diseases in developing countries.

cpbannerad300x150new2gif
rauconbadgejpg
e78banner300x150animgif
cpbannerad300x150new1gif
rauconbadgejpg
e78banner300x150animgif